Search
Tiazofurine
go.drugbank.com/drugs/DB13243ExperimentalTiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].
Radalbuvir
go.drugbank.com/drugs/DB12065InvestigationalRadalbuvir has been used in trials studying the treatment of Chronic Hepatitis C, Chronic HCV Infection, and Chronic Hepatitis C Infection.
5-Hydroxymethylfurfural
go.drugbank.com/drugs/DB12298InvestigationalAes-103 has been used in trials studying the treatment and prevention of Hypoxia, Anemia, Sickle Cell, and Sickle Cell Disease.
Cytochlor
go.drugbank.com/drugs/DB12383InvestigationalCytochlor has been used in trials studying the treatment of Head and Neck Cancer and Brain and Central Nervous System Tumors.
HSD-016
go.drugbank.com/drugs/DB12419InvestigationalHsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).
AMG-208
go.drugbank.com/drugs/DB08079InvestigationalAMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.
Obatoclax
go.drugbank.com/drugs/DB12191InvestigationalObatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.
SYNB1891
go.drugbank.com/drugs/DB17541InvestigationalSYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. … [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects).
WX-554
go.drugbank.com/drugs/DB21749InvestigationalWX-554 is under investigation in clinical trial NCT01581060 (Phase I/​II Dose-escalation Study to Investigate Safety and Pharmacokinetics/​ Pharmacodynamics of WX-554 in Patients With Solid Tumours).
QR-1123
go.drugbank.com/drugs/DB17869InvestigationalQR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (_RHO_) gene.[L46782]